Rational drug design at the blood-brain barrier

In order to be efficient as a therapeutic agent CNS (central nervous system)-acting drugs must cross the blood-brain barrier (BBB) and enter into the brain. The existing and new biomedical approaches for the rational design of novel CNS-active nanocarriers and prodrugs to improve drug delivery play an important role by enhancing drug passive and active BBB transport. These drug delivery vectors can be applied for the treatment of many neurologic conditions including Alzheimer's or Parkinson's diseases neuroinfections (meningitis and encephalitis) hemorrhagic and ischemic stroke and traumatic brain injury.